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1. Introduction
The use of prosthetic devices for breast reconstruction began in the early 1960’s with silicone-
gel filled implants. Currently, traditional two-stage tissue expander to implant prosthetic
breast reconstruction remains the most common type of breast reconstruction performed in
the United States. Most recent ASPS statistics estimate greater than 70% of reconstructions are
implant based.[1]
Over the years, implant technology and surgical techniques have evolved, resulting in the
improved outcomes in breast reconstruction. National trends have moved away from total
submuscular coverage toward “dual-plane” positioning of implants. Dual-plane placement
provides multiple advantages including decreased chest wall morbidity and increased patient
comfort. However, limitations of dual-plane positioning include lack secure coverage of the
inferior pole of the implant, less control over the position of the inframammary fold (IMF), and
a tendency towards superior migration of the pectoralis major muscle and expander during
expansion. [2]-[4] Additional limitations of traditional tissue expander reconstruction remains
the time required to reach maximal expansion and difficulty in inferior pole expansion. [5]
Acellular dermal matrix (ADM), was initially employed in breast surgery for revision breast
augmentation to prevent rippling and contour abnormalities. It is currently being utilized to
address the limitations associated with the dual plane and total submuscular techniques.[6]
Its use in immediate implant based breast reconstruction became popular in 2005 after Brueing
et al. published a case series describing its use as a sling to cover the inferior-lateral pole in
immediate permanent implant reconstruction.[5],[4]Subsequently several case series were
published to further support this technique and expand its use to two-stage tissue expander
reconstruction. [3],[7]-[11]Proponents of this technique advocate two main advantages:
inferior-lateral pole coverage of the implant where the pectoralis muscle is absent and greater
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initial tissue expansion. [7],[11]-[14][16]-[18]Other proposed advantages include decreased
postoperative pain, decreased donor site morbidity, and improved aesthetic outcomes. Several
disadvantages have been proposed in the literature including increased postoperative
infectious complications, seroma, and explantation.[13],[19]-[21] (Figure 1)
Figure 1. Placement of Accellular Dermal Matrix
Breast Reconstruction - Current Perspectives and State of the Art Techniques68
2. Types of acellular dermal matrix
While the majority of breast reconstruction with acellular dermal matrix has been described
with the use of human matricies, porcine and bovine products are available and have been
described for use. Human acellular dermal matricies published in the literature for use in breast
reconstruction include; Alloderm (LifeCell, Branchburg, NJ), Flex HD (Ethicon, Sommerville,
NJ), Neoform (Mentor, Santa Barbara, CA), DermaMatrix (Synthes, West Chester, PA). Porcine
derived matrices include; Strattice (LifeCell, Branchburg, NJ) and Permacol (Covidien,
Boulder, CO). Currently there is only one bovine dermal matrix on the market, Surgimend
(TEI Biosciences, Boston, MA).
3. Timing
Prosthetic breast reconstruction with acellular dermal matrix can be accomplished either in
the immediate or delayed fashion. The advantage of immediate reconstruction is that the first
step of breast reconstruction is accomplished at the time of the mastectomy under the same
general anesthesia. In this setting, maximum amount so breast skin can be preserved as the
prosthetic device will occupy some of the mastectomy space. In the setting of single stage breast
reconstruction using a permanent implant, immediate reconstruction allows for the placement
of an optimally sized device.
Delayed breast reconstruction using this technique is also possible, however, significantly
more tissue expansion is generally necessary. In this method, the mastectomy skin flaps are
re-elevated and expanded postoperatively to re-create a pocket for the ultimate placement of
a permanent breast implant. Although delayed breast reconstruction with a tissue expander
requires an intraoperative procedure, it benefits from simplification of the initial phase of
patient management. In the setting of high-risk disease and patients who may require
chemotherapy and radiation therapy, delayed reconstruction will not result in a delay of
initiation of the adjuvant treatments.
4. Patient selection
While the majority of patients are candidates for prosthetic breast reconstruction and addi‐
tionally prosthetic reconstruction with acellular dermal matrix. There are several limitations
with the overall shape of the permanent implants that dictate the quality of the final result.
Factors to consider include need for bilateral or unilateral reconstruction, the patients overall
body habitus including body mass index (BMI) and chest width, comorbidities, and patients
psychological profile. The ideal candidates for prosthetic reconstruction with acellular dermal
matrix are thin patients undergoing bilateral breast reconstruction with adequate mastectomy
skin flaps and thin patients with a non-ptotic breast undergoing unilateral reconstruction with
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adequate mastectomy skin flaps. In these situations, achieving reasonable symmetry is
typically achievable.
However, as both breast size and degree of ptosis increases, symmetry in unilateral prosthetic
breast reconstruction becomes more difficult to achieve. In this setting, patients may be
candidates for contralateral symmetry procedures such as mastopexy or reduction mammo‐
plasty. While the ultimate goal is to provide exact symmetry, patients should be aware that
symmetry may only be accomplished in brassiere and clothing.
While there are no defined absolute contraindications for use of Acellular dermal matrix in
prosthetic breast reconstruction, obesity, smoking history, and breast size >600grams have
been shown to be associated with increased rates of postoperative complications. [19]-[21]
5. Technique
The primary goal of prosthetic breast reconstruction is to achieve a breast mound that is
symmetric with either the normal contralateral breast or the contralateral reconstruction. Clear
communication between the ablative and reconstructive surgeons is necessary to achieve
superior results. Mastectomy incisions are planned and marked together and the inframam‐
mary fold should additionally be marked and preserved when possible. Additionally,
mastectomy skin flaps should be of adequate thickness to maintain blood supply to the skin
and prevent mastectomy skin flap loss.
After mastectomy, careful hemostasis should be obtained within the mastectomy pockets.
Then the inferolateral origin of the pectoralis major muscle, along with the investing fascia, is
elevated off the anterior chest wall. Using electrocautery dissection, a subpectoral pocket is
developed to the extent of the previously marked perimeter of the breasts. After the pocket
has been successfully developed, an appropriately sized, usually 4-8cm x 14-16cm, sheet of
acellular dermal matrix is prepared according to the manufacturer’s recommendations. The
ADM is then sutured to chest wall to recreated the inferior and lateral mammary folds. Most
surgeons prefer the use of an absorbable suture including either 2-0 polydioxanone (PDS)
(Ethicon, Somerville, NJ) or 2-0 Vicryl (Ethicon, Sommerville, NJ) suture. The inframammary
ADM is curved laterally and cephalad along the lateral border of the breast perimeter to
recreate the natural curvilinear origins of the inferolateral aspect of the detached pectoralis
muscle and breast mound unit. Once the ADM has been secured to the inframammary fold,
the width of the pocket is measured and tissue expander size is chosen based on the base width.
Hemostasis in the pocket is then meticulously achieved. The tissue expander is then prepared
in the standard sterile fashion on the back table and then placed in the pocket. The superior
border of the ADM is sutured to the inferior and lateral border of the pectoralis muscle thus
creating and inferolateral sling of ADM. (Figure 2 and Figure 3)
This tissue expander can be inflated intraoperatively to a volume determined appropriate by
surgeon judgment. Care is taken to obliterate dead space but to not impart excessive pressure
on the mastectomy skin flaps. One or two closed suction drains are utilized to drain the
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mastectomy space. The mastectomy skin flaps can be tailored to remove excess or non-viable
skin prior to final closure. (Figure 4)
Figure 2. Intraoperative illustration of tissue expander placement into the pectoralis major and acellular dermal ma‐
trix pocket
Figure 3. Intraoperative closure of pectoralis major and acellular dermal matrix over the tissue expander
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Figure 4. Intraoperative tissue expansion
6. Expansion
Tissue expansion begins in the office approximately 10-14 days after surgery when wound
healing is stable and patient no longer has pain. Tissue expansion ensues in the standard
fashion using the magnetic expander port finding device to find the site of the valve. The area
is then cleansed with antiseptic solution and butterfly needle is used to gain access to the tissue
expander. Approximately 30-120mL of saline is injected into the expander during each
expansion session. Expansions typically occur at weekly to monthly intervals. The final goal
of expansion is guided by desired reconstruction breast size and/or achieving maximum
symmetry with contralateral breast. Overexpansion (greater than tissue expander volume)
helps to create ptosis in the secondary exchange procedure. In general, soft tissues are allowed
to rest for at least one month between the time of last expansion and the implant exchange
procedure. [22] (Figure 5)
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7. Proposed advantages
ADM was initially described for use in single stage immediate permanent implant reconstruc‐
tion and one proposed advantage of the use of ADM is to decrease or eliminate the use of tissue
expanders. In the initial report by Breuing, and five subsequent retrospective studies, the
efficacy and success of one stage reconstruction has been shown. [7],[9],[12],[14],[15],[23] In
these retrospective reviews the overall complication rate is found to be between 6.9% and 25%.
[24] Breuing reports a 6.9% (2/30) complication rate in single state reconstructions and
Zienowicz’s et al. shows a complication rate of 25% (6/24) all of which were mastectomy skin
flap necrosis, treated only with local wound care.[12],[25] The largest review of immediate one
stage implant reconstructions by Colwell et al. describes an overall complication rate of 14.8%
(49/331), including 9.1% (30/331) cases of mastectomy skin flap necrosis. Of the cases of
mastectomy skin flap necrosis five implants (1.5%) required explantation. 9 These results
demonstrate the successful use of ADM as an adjunct to immediate one stage permanent
implant reconstruction. However, it is important to realize, one stage reconstruction is not
Figure 5. 49 year old female with left breast cancer who underwent left mastectomy with acellular dermal matrix and
tissue expander followed by exchange for permanent implant.
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always possible in patients undergoing prosthetic reconstruction. In order to achieve maxi‐
mum success in direct to implant reconstruction, proper patient selection is paramount.
Specifically, the heath and viability of mastectomy skin flaps needs to be excellent and although
it may be possible to make the reconstructed breast slightly larger than the native breast, ideal
direct to implant candidates desire a similar or smaller sized reconstructed breast.[9]
Another proposed advantage of ADM is decreased postoperative pain associated with
traditional dual plane or total submuscular implant placement due to less extensive muscle
elevation and dissection.[5],[26] Several retrospective reviews in the literature have addressed
this issue and while subjectively pain was shown to be diminished in patients being recon‐
structed with ADM. There are no studies that demonstrate objective data with statistical
significance to support this claim. [10],[11],[15] However, a recent prospective randomized
trial revealed no difference in postoperative pain when comparing total submuscular coverage
to the patients undergoing reconstruction with ADM sling. [27]
Decreased operative time is another heralded advantage of ADM however, there is an absence
of data in the literature proving this statement. There is anecdotal evidence in two case series
suggesting this benefit. [5],[14]
Increased initial TE fill is a seemingly logical benefit to the use of acellular dermal matrix. The
sling allows greater size of implant pocket and easier expansion within the pocket with less
muscular recoil. This has been proven in many retrospective investigations with differences
in initial tissue expander volumes as high as 300mL. [8],[12],[15]-[17],[19]-[21],[24] Two studies
thwart this evidence, Preminger et al. comment that there is no statistically significant
difference in expansion of the ADM cohort when compared to the non-ADM cohort at 224 mL
versus 201 mL (p=0.180). [28] However, this approaches significance and sample size alone
may prove the limitation of this particular value. Additionally, Vardanian et al. saw a similar
fill in the ADM cohort at 150 ± 76mL as compared to 100 ± 69 mL in the non-ADM cohort.[29]
However, it is important to realize that the factors contributing to increased tissue expander
fill including body habitus, mastectomy skin flap condition, type of mastectomy performed
(skin sparring, nipple areolar sparing), and surgeon judgment play roles in determining
amount of tissue expander fill.
In addition to initial greater tissue expander fill, fewer number of overall expansions is another
seemingly logical extension of the use of the ADM sling. Several studies have addressed this
issue, however, the data is not as convincing. Four studies show that a statistically significant
fewer numbers of expansions is required with the addition of ADM. [3,7,8,30] Sbitany shows
a decreased total number of fills in the ADM group at 1.7 when compared to the non-ADM
group at 4.3. 8 Similarly, Nahabedian reports a mean number of expansions in the ADM group
at 3 as compared to the non-ADM group at 5.5. [7] On the other hand four studies have shown
no difference in the number of expansions when comparing each cohort. [10],[17],[27],[28] Seth
demonstrates an average number of expansions in the ADM group of 4.8 ± 2.4 as compared to
the non-ADM group of 5.3 ± 2.4 (p=0.02).[17] Similarly, McCarthy in a prospective randomized
trial shows no difference in time to completion of expansion at 5.6 months in the ADM cohort
when compared 4.6 months in the non-ADM cohort (p=0.93). [27]
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Several theories can explain the striking schism in the data regarding time to expansion, major
factors accounting for these equivocal findings include surgeon technique and patients
physical limitations. Some surgeons and institutions are more aggressive with tissue expansion
volumes and time between expansions. Additionally, patients’ ability to tolerate expansions
is extremely variable. Given, this information, this proposed advantage is not likely clinically
relevant.
Acellular dermal matrix was initially described for use in revision breast augmentation to treat
capsular contractures. A natural translation would be to prevent capsular contractures in those
undergoing breast reconstruction. Capsular contracture has been reported in rates as high as
14.1% in patients undergoing reconstruction without ADM.[31] Several authors have touted
an absence of capsular contracture with ADM with follow up times ranging from 6.5 to 52
months. [5],[6],[11],[15],[23],[32] Vardanian et al. showed in a recent retrospective review that
capsular contracture severity, as graded by modified Baker capsular contracture grading
system, was significantly lessened in patient undergoing reconstruction with the addition of
ADM.[29] Additionally, studies have not shown Baker capsular contracture grades greater
than grade I or II.[10],[12] In a primate model Stump et al. evaluated the effect of ADM on
capsule formation and found at 10 weeks there was no definable capsule in around the
implants reconstructed with ADM compared to the implants without which had a definable
capsule. To date, there is no long term data to support a protective effect of ADM to in reducing
the incidence of capsular contracture.
Improved aesthetic outcomes of reconstructed breasts are the ultimate goal of plastic surgeons.
However, evaluation of this outcome is very subjective and surgeon dependent. Many authors
have argued that ADM provides better aesthetic outcomes but there is sparse data to support
these claims. Two studies have objectively evaluated the aesthetic outcomes of breast recon‐
struction with ADM. Spear et al. defined a five-point scale and compared ADM reconstructed
breast to contralateral non-reconstructed breasts. They found that scores for breast recon‐
structed with ADM did not significantly differ from the contralateral unreconstructed breast
at 3.68 versus 3.98 (p =0.3). [3] Additionally, Vardanian et al. showed that overall aesthetic
outcomes, graded by four independent observers on a scale of 1-4, was statistically significantly
greater in the ADM group at 3.26 when compared to the non-ADM group at 2.87. Additionally,
the inframammary fold was found to be in better position in the ADM group at 3.35 as
compared to the non-ADM group at 2.94. [29]
8. Complications
Complications associated with prosthetic breast reconstruction with acellular dermal matrix
are similar to those reconstructed without acellular dermal matrix and should be divided into
early and late complications. Early complications include; hematoma, seroma, mastectomy
skin flap necrosis, infection, and need for explantation. Late complications include: asymme‐
try, implant wrinkling, malposition, capsular contracture, and late infection.
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The incidence of hematoma is generally accepted as less than 5%. The treatment and conse‐
quences are similar with all breast reconstruction. This involves identification of hematoma
and rapid evacuation to prevent sequelae, which includes mastectomy skin flap compromise,
infection, and capsular contracture.
Seroma, unlike hematoma, is fraught with much controversy in the face of acellular dermal
matrix. ADM is hypothesized to increase the risk of seroma and two studies show statistically
significantly higher incidences of seroma. [13],[16] Chun shows seromas at an incidence of
14.1% in the ADM cohort when compared to non-ADM cohort at 2.7%. [13] Similarly, Parks
shows an incidence of 29.9% in the ADM cohort when compared to 15.7% in the non-ADM
cohort.[16] However, there are many studies that do not show a statistically significant
difference in the incidence of seroma associated with ADM. [17],[19]-[21],[29],[33] Many of
these studies including Liu at 7.1% in the ADM group versus 3.9% in the non-ADM group and
Lanier at 13.4% in the ADM group versus 6.7% in the non-ADM group approach but fail to
reach statistical significance. [19],[21] Given these findings it is important to take minimize the
risk of seroma, including wide drainage with closed suction drains placed in the subcutaneous
pocket plus or minus the expander/implant pocket and careful measurements of outputs to
avoid premature drain removal.
Mastectomy skin flap necrosis is always a major concern in the setting of prosthetic breast
reconstruction. Given the primary surgical intent of mastectomy is to treat breast cancer or
remove all breast tissue to prevent cancer development, mastectomy skin flap thickness is often
indeterminate. Additionally, other factors such as length of the mastectomy skin flap, medical
comorbidities, smoking history, and surgical technique can often contribute to the develop‐
ment of mastectomy skin flap necrosis. Superficial or partial-thickness flap necrosis can be
managed conservatively with local wound care. However, full thickness necrosis in the setting
of an ADM assisted reconstruction should be managed with early excision with temporary
deflation of expander to facilitated tension free closure and subsequent expansion.[34]
Mastectomy skin flap necrosis associated with overt prosthetic exposure typically results in
explantation. It is important to realize that ADM represents a second foreign body in addition
to the expander/implant. Secondary infection of both the expander/implant and ADM is
possible with the presence of mastectomy skin flap necrosis.
While there is no direct association between mastectomy skin flap necrosis and acellular
dermal matrix, the incidence of mastectomy skin flap necrosis has been seen to be higher in
patients undergoing reconstruction with ADM in two series. Weichman et al. reports a
mastectomy skin flap necrosis rate of 8.3% in the ADM cohort as compared to 3.2% in the non-
ADM cohort and Chun et al. similarly shows an incidence of 23.4% in the ADM cohort as
compared to 8.9% in the non-ADM cohort. [13],[20] Both series also show greater initial tissue
expansion volume, which is thought to contribute to this increased incidence. Therefore, it is
important to both prevent mastectomy skin flap necrosis through surgical judgment and
careful inflation of initial tissue expander. Additionally, it is paramount to identify full
thickness necrosis and treat expeditiously with excision and closure to prevent further sequlae.
Some authors support the use of indocyanine green angiography to assess the mastectomy
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skin flap viability. However, the data to support this technology available in the literature is
inconclusive.
Infectious complications of prosthetic breast reconstructions are cited as high as 35.4%.[35],[36]
Reconstruction with the addition of ADM poses a second foreign body and therefore infectious
complications could be more likely. The literature displays divergent evidence with regards
to infectious complications in the presence of ADM. There are a multitude of reports showing
equivalent infectious complications when comparing ADM to non-ADM breast reconstruc‐
tions. [3],[7-9],[15]-[18],[29],[37],[38]Conversely there are many reports showing increased
infectious complications in patients with ADM reconstruction. [13],[19]-[21],[33] It is important
to recognize infectious complications and treat expeditiously with either oral or intravenous
antibiotics as per surgeon judgment.
9. Conclusions
Acellular dermal matrix is an influential addition to the plastic surgical armamentarium for
breast reconstruction. Superior aesthetic results have been seen in patients undergoing both
immediate one-stage implant reconstructions and two-stage tissue expander reconstruction.
Surgeons should realize, however, that ADM is another tool in prosthetic breast reconstruction
and not necessarily a panacea. Surgeon judgment based upon experience and evidence based
best practices should guide the use of ADM in prosthetic breast reconstruction.
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